Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study - Centre Eugène Marquis
Article Dans Une Revue Acta Dermato-Venereologica Année : 2024

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study

Résumé

Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp’s real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.
Fichier principal
Vignette du fichier
41297.pdf (748.66 Ko) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

inserm-04839709 , version 1 (16-12-2024)

Licence

Identifiants

Citer

Lucille Vitek, Thomas Goronflot, Caroline Dutriaux, Antoine Deleuze, Yannick Le Corre, et al.. Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study. Acta Dermato-Venereologica, 2024, 104, pp.adv41297. ⟨10.2340/actadv.v104.41297⟩. ⟨inserm-04839709⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More